Managed Healthcare Executive February 24, 2024
Peter Wehrwein, Managing Editor

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

The FDA has approved Simlandi (adalimumab-ryvk), which joins Pfizer’s Abrilada (adalimumab-afzb) and Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) as interchangeable with AbbVie’s Humira’s (adalimumab), the reference brand-name product that has set all kinds of sales records, for some uses.

Interchangeability means the biosimilar can be substituted for the reference product or another biosimilar at the pharmacy level, although state-level pharmacy regulations can complicate matters. Interchangeability is widely seen as important for gaining market share in the increasingly crowded market for Humira biosimilars and for pharmacy benefit managers (PBMs) steering prescriptions to their preferred products.

A total of nine Humira biosimilars are on the market in the U.S.,...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA wants to boost trial innovation with new center at CDER
Stelara biosimilar from Alvotech, Teva approved by FDA
Scopio Labs Receives FDA Clearance For AI-Driven Bone Marrow Analysis Application
STAT+: Grocers are pushing legislation they claim would enhance food safety. Advocates say it would gut FDA rules
Look Before You Leap - Early Determination Of Product Classification And Regulatory Pathway For FDA-Regulated Products

Share This Article